Clinical Trial Update: Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combined tretinoin and arsenic trioxide for newly diagnosed acute promyelocytic leukemia with risk-adapted postremission therapy; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• TRETINOIN (TRETINOIN)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Promyelocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-11-30